Remdesivir is an investigational nucleotide analog with broad-spectrum antiviral activity. It is an experiemental medicine that is not approved for any use, developed by Gilead. Remdesivir has demonstrated in vitro and in vivo activity in animal models against MERS and SARS, which are also coronaviruses. The preliminary data indicates that remdesivir may have potential activity against COVID-19.